In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response.
Plasmacytoid dendritic cell (PDC) leukemia/lymphoma is a rare neoplasm presenting cutaneous lesions at the time of diagnosis, followed by dissemination to bone marrow, lymph nodes, and other lymphoid and nonlymphoid organs. Since these leukemic counterparts of human PDC are similar to normal PDC, we studied their chemokine receptor equipment and their migratory capacities. We found both in skin lesions and in invaded lymph nodes an expression by tumor cells of CXCR3, CXCR4, and CCR7, and the concomitant expression by cells in the microenvironment of their respective ligands CXCL9, CXCL12, and CCL19. Moreover, flow cytometry phenotype of leukemic PDC (LPDC) revealed an unexpected expression of CCR6. We show that fresh tumor cells are able to migrate in response to CXCR4, CCR2, CCR5, CCR6, and CCR7 ligands, and the ability of CXCR3 ligands to increase the responsiveness to CXCL12. IL-3- or virus-induced activation of LPDC leads to downregulation of CXCR3 and CXCR4, and upregulation of CCR7, associated with the loss of response to CXCL12, and the acquisition of sensitivity to CCL19. Altogether, these results suggest that the preferential accumulation of LPDC in the skin or lymph nodes could be orchestrated by CXCR3, CXCR4, CCR6, and CCR7 ligands, found in nontumoral structures of invaded organs.
Schering Plough Laboratory for Immunological Research, Dardilly, France.
N
N
Bendriss-Vermare
L
L
Chaperot
M
M
Peoc'h
B
B
Vanbervliet
M-C
MC
Jacob
F
F
Briere
J-C
JC
Bensa
C
C
Caux
J
J
Plumas
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002465:Cell Movement; D054415:Chemokine CCL19; D054377:Chemokine CXCL12; D054370:Chemokine CXCL9; D019742:Chemokines, CC / Q000378:metabolism; D019743:Chemokines, CXC / Q000378:metabolism; D002633:Chemotaxis; D002648:Child; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D066298:In Vitro Techniques; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D007938:Leukemia / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D008024:Ligands; D008198:Lymph Nodes / Q000378:metabolism* / Q000473:pathology; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010950:Plasma Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D054400:Receptors, CCR7; D054367:Receptors, CXCR3; D019718:Receptors, CXCR4 / Q000378:metabolism*; D019707:Receptors, Chemokine / Q000378:metabolism*; D012871:Skin Diseases / Q000378:metabolism* / Q000473:pathology
C515460:CCL19 protein, human; C515370:CCR7 protein, human; C515255:CXCL12 protein, human; C080810:CXCL9 protein, human; C515187:CXCR3 protein, human; D054415:Chemokine CCL19; D054377:Chemokine CXCL12; D054370:Chemokine CXCL9; D019742:Chemokines, CC; D019743:Chemokines, CXC; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D054400:Receptors, CCR7; D054367:Receptors, CXCR3; D019718:Receptors, CXCR4; D019707:Receptors, Chemokine